Identification and validation of an H2AZ1-based index model: a novel prognostic tool for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Identification and validation of an H2AZ1-based index model: a novel prognostic tool for hepatocellular carcinoma

Published:2024-02-01 Issue: Volume: Page:
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Gao Jiamin¹²³,Lu Qinchen²³,Zhong Jialing²³⁴,Li Zhijian²³⁴,Pan Lixin²³,Feng Chao²³,Tang Shaomei²³,Wang Xi²³,Tao Yuting²³,Zhou Xianguo²³⁵,Wang Qiuyan²³

Affiliation:

1. Laboratory of Infectious Disease, Nanning Infectious Disease Hospital Affiliated to Guangxi Medical University and The Fourth People’s Hospital of Nanning, Nanning, China

2. Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China

3. Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China

4. Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

5. Department of Blood Transfusion, Guangxi Medical University Cancer Hospital, Nanning, China

Publisher

Impact Journals, LLC

Reference59 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.;Bray;CA Cancer J Clin,2021

2. International trends in liver cancer incidence rates.;Jemal;Cancer Epidemiol Biomarkers Prev,2011

3. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.;Boige;Eur J Cancer,2015

4. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma.;Lo;Br J Surg,2017

5. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.;Rela;Ann Hepatol,2017